Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03419533
Other study ID # HREC/16/WCHN/140_3
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 1, 2018
Est. completion date December 31, 2020

Study information

Verified date October 2021
Source University of Adelaide
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is an observational cross sectional study to evaluate the impact of a 4CMenB vaccination program on oropharyngeal N. meningitidis carriage in vaccinated and unvaccinated school leavers.


Description:

This carriage study of a cohort of school leavers in South Australia (SA) will provide an opportunity to assess carriage rates in the young adult population (school leavers) following introduction of a 4CMenB vaccination program in senior school students from 2017-2018.This will allow a comparison of carriage prevalence in the two years (2018 and 2019) following implementation of the school program to assess impact on carriage at a population level and compare carriage prevalence in vaccinated versus non-vaccinated groups. Assessment of any association between risk factors and prevalence of nasopharyngeal carriage in school leavers will be made and compared between vaccinated and unvaccinated students. School leavers are defined as students who were enrolled in year 12 at school in the preceding year of recruitment and have been chosen as they are likely to have the highest carriage rates. A high proportion (approximately two thirds) of students will be immunised by the time of throat swab collection in years 2018 and 2019. Assessing carriage in both vaccinated and unvaccinated cohorts will further inform the effect of 4CMenB vaccine on carriage at a population level. This will help determine any herd immunity impact of 4CMenB vaccine and persistence of any effect.


Recruitment information / eligibility

Status Completed
Enrollment 6802
Est. completion date December 31, 2020
Est. primary completion date December 31, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 17 Years to 25 Years
Eligibility Inclusion Criteria: - South Australian school leavers between 17 to 25 years of age (enrolled in year 12 in the previous year ie year 2018, students are eligible if they were enrolled in year 12 in 2017, year 2019, students are eligible if they were enrolled in year 12 in 2018). Exclusion Criteria: - No exclusion criteria

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Australia Women's and Children's Hosptial Adelaide South Australia

Sponsors (1)

Lead Sponsor Collaborator
University of Adelaide

Country where clinical trial is conducted

Australia, 

References & Publications (1)

Marshall HS, McMillan M, Koehler A, Lawrence A, MacLennan J, Maiden M, Ramsay M, Ladhani SN, Trotter C, Borrow R, Finn A, Sullivan T, Richmond P, Kahler C, Whelan J, Vadivelu K. B Part of It School Leaver protocol: an observational repeat cross-sectional study to assess the impact of a meningococcal serogroup B (4CMenB) vaccine programme on carriage of Neisseria meningitidis. BMJ Open. 2019 May 6;9(5):e027233. doi: 10.1136/bmjopen-2018-027233. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Describe Carriage Density of N. Meningitidis Genogroups as Measured by qPCR in School Leavers Density of N. meningitides by qPCR 2018 to 2019
Other Describe Genome Sequencing of Pathogenic N. Meningitidis (A, B, C, W, X, Y) in Carriage Among School Leavers. Whole genome sequencing of N. meningitidis 2018 to 2019
Primary Estimate the Difference in Carriage Prevalence of Disease Associated Genogroups of N. Meningitidis (A, B, C, W, X, Y) Between School Leavers in 2018 (Year 12 in 2017) and 2019 (Year 12 in 2018), Following a 4CMenB School Immunisation Program As measured by PCR in school leavers in 2018 and 2019 2018 to 2019
Secondary Estimate the Difference in Carriage Prevalence of All N. Meningitidis Genogroups Between South Australian School Leavers in 2018 (Year 12 in 2017) and 2019 (Year 12 in 2018) As measured by PCR in school leavers in 2018 and 2019 2018 to 2019
Secondary Estimate the Difference in Carriage Prevalence of Each N. Meningitidis Genogroup (A, B, C, W, X, Y) Between South Australian School Leavers in 2018 (Year 12 in 2017) and 2019 (Year 12 in 2018) As measured by PCR in school leavers in 2018 and 2019 2018 to 2019
Secondary Across Years, Estimate the Difference in Carriage Prevalence of N. Meningitidis Genogroups Causing Disease (A, B, C, W, X, Y) Between South Australian School Leavers Who Received 4CMenB Vaccine and Unvaccinated Students As measured by PCR in vaccinated and unvaccinated school leavers 2018 to 2019
Secondary Across Years, Estimate the Difference in Carriage Prevalence of All N. Meningitidis Genogroups Between South Australian School Leavers Who Have Received 4CMenB and Unvaccinated Students. As measured by PCR in vaccinated and unvaccinated school leavers in 2018 and 2019 2018 to 2019
Secondary Across Years, Estimate the Difference in Each N. Meningitidis Genogroup (A, B, C, W, X, Y) Carriage Prevalence Between South Australian School Leavers Who Received 4CMenB Vaccine and Unvaccinated Students As measured by PCR in vaccinated and unvaccinated school leavers 2018 to 2019
Secondary Identify Characteristics Associated With Carriage Prevalence of All N. Meningitidis Genogroups in South Australian School Leavers in 2018/2019 As measured by PCR in school leavers 2018 to 2019
Secondary Identify Characteristics Associated With Carriage Prevalence of N. Meningitidis Genogroups Causing Disease (A, B, C, W, X, Y) in South Australian School Leavers in 2018 /2019 As measured by PCR in school leavers 2018 to 2019
See also
  Status Clinical Trial Phase
Completed NCT01218451 - NeisVac-C Single Prime Study in Infants Phase 3
Completed NCT00323050 - Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects Phase 3
Completed NCT01090453 - Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants Phase 2
Completed NCT00454987 - Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine Phase 4
Completed NCT00891176 - Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines Phase 3
Completed NCT01839188 - Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010) Phase 3
Completed NCT01553279 - Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) Phase 3
Completed NCT00263653 - Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197 Phase 3
Completed NCT00772070 - Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine Phase 2
Completed NCT00129116 - 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age Phase 2
Completed NCT00127855 - Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine Phase 2
Completed NCT00871338 - Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants Phase 2
Completed NCT00700635 - Dose Comparison Study of Menactra® in US Children Phase 2
Completed NCT00326118 - Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years. Phase 3
Completed NCT01730391 - Neisseria Meningitidis Burden of Disease Study N/A
Completed NCT00197795 - Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults Phase 2
Completed NCT00289783 - Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine Phase 3
Completed NCT00444951 - Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia Phase 3
Completed NCT00258700 - Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine Phase 3
Completed NCT01978093 - Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age Phase 3